.jpg)
.png)
NLA News
An International Masters in Lipidology course debuted in Sydney, Australia in late October 2010. The international faculty included: Dr. Gerald Watts Dr. John Chapman, President of the European Atherosclerosis Society Dr. Richard O'Brien Dr. David Sullivan, Past President of the... more
August President's Message Dr. Joseph Saseen takes a look ahead at what is to come for the NLA, including LipidPALOOZA in September!
Olezarsen met the primary endpoint with a statistically significant reduction in triglyceride levels versus placebo First study to show an absolute reduction in acute pancreatitis in FCS patients, with olezarsen 80 mg monthly dose reducing events by 100 percent... more
In 2014, the Foundation of the National Lipid Association (FNLA), Preventive Cardiovascular Nurses Association (PCNA), and Mended Hearts launched Cholesterol Counts, a program designed to accumulate Internet-based information on how much people know about their cholesterol, how much they care about... more
By Carl E. Orringer, MD, FACC; Pamela Bowe Morris, MD, FACC; Donald M. Lloyd-Jones, MD, FACC Guideline-directed patient care recommendations are based upon studies that make observations on groups of subjects who have specific characteristics and exhibit variable degrees of benefit or harm... more
MIAMI, Fla. – (May 16, 2019) – Findings of the first patient statin use survey based on a comprehensive set of patient experiences and behavioral markers were presented today at the National Lipid Association’s (NLA) 2019 Scientific Sessions. The Statin Adverse Treatment... more
The NLA is excited to share that we will host our first-ever virtual Scientific Sessions! Due to current travel restrictions and gathering limitations in the city of Chicago, the NLA has made the difficult decision to rescope our 2020 Scientific Sessions into a fully virtual conference held live on... more
Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and... more
The National Lipid Association (NLA) was in attendance at the recent American College of Cardiology (ACC) Annual Scientific Session and Expo 2015, March 14-16, in San Diego. The meeting was dedicated to the diagnosis, prevention and treatment of cardiovascular disease, taking an interactive and... more
FOURIER Trial Reveals Significant Reduction in Cardiovascular Risk Study results indicate that evolocumab significantly reduces the risk of cardiovascular events in patients with clinically evident ASCVD WASHINGTON, D.C., March 17, 2017 — The FOURIER trial lead investigators... more